Drug intelligence / Profile preview

Celixir15

Development stage: Unknown
Lead developer: BOL Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Celixir15** is a BOL Pharma marketed medical-cannabis medicated-drop product labelled T3/C15, containing approximately 3% tetrahydrocannabinol and 15% cannabidiol. It is a CBD-dominant cannabinoid oil formulation. BOL Pharma produces medicated drops with standardized cannabidiol and tetrahydrocannabinol ratios using whole-plant extracts and isolated-cannabinoid formulations; public materials do not specify which production line applies specifically to Celixir15. Reported indications include adult epilepsy and fibromyalgia. ([bolpharma.com](https://www.bolpharma.com/our-products/))

Brand names: Celixir15Celixir-15Celixir 15
Other names: Celixir 15Celixir15Celixir-15סליקסיר15

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Celixir15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celixir15.

Explore the full profile